The intravenous infusion of rat adrenomedullin, at concentrations ranging from 0,1 to 1.0 I-Lg/kg/min, for 60 min increased the regional cerebral blood flow (rCBF) in a dose dependent manner in rats. rCBF was measured using a laser Doppler flowmetry device placed on the surface of the parietal cortex. The increase in rCBF induced by 1.0 I-Lg/kg/min of adrenomedullin was up to 145 ± 10.8% of controls at 60 min (n = 5, p < 0.001). These concentrations of adrenomedullin did not affect systemic blood pressure or other physiologic param eters, including pH, P ac02, P a02, hemoglobin, and blood glu cose. Repeated infusion of 1.0 I-Lg/kg/min of adrenomedullin at 2-h intervals caused tachyphylaxis (n = 5, p < 0.01). Rat adrenomedullin (1.0 I-Lg/kg/min) demonstrated a more potent effect than the same dose of human adrenomedullin. The C terminal fragment of human adrenomedullin (0.5 and 5.0 I-Lg/
kg/min), adrenomedullin22_52, which did not affect rCBF alone, inhibited the effect of rat adrenomedullin (0.5 I-Lg/kg/min) as a receptor antagonist in a dose-dependent manner. In a model of middle cerebral artery (MCA) occlusion in spontaneously hy pertensive rats, pre-and postinfusion of 1.0 I-Lg/kg/min of ad renomedullin suppressed the reduction in rCBF following MCA occlusion (control, 29 ± 15.1 %; adrenomedullin group, 45 ± 14.4%; not significant) and decreased the volume of isch emic brain injury (control, 288 ± 35 mm 3 ; adrenomedullin group, 232 ± 35 mm 3 ; p < 0.05). These results suggest that adrenomedullin increases rCBF and prevents ischemic brain injury, partly by increasing the collateral circulation. Key Words: Adrenomedullin-Regional cerebral blood flow NIH Image-Spontaneously hypertensive rats-Middle cere bral artery occlusion. submandibular glands, and to a lesser extent in the cen tral nervous system (Kitamura et aI., 1993b; Ichiki et aI., 1994) . However, recent studies have shown that high concentrations of adrenomedullin are detected in many regions of human brain, with the highest concentrations in the thalamus and hypothalamus, and is also expressed in such pathological conditions as neoplasma or ischemic injury (Satoh et aI., 1995; Wang et aI., 1995) . It has been demonstrated that the binding sites for adrenomedullin are localized with immunoreactive adrenomedullin in the same tissues (Owji et aI., 1995) .
It is known that the exogenous application of adreno medullin elicits potent, long-lasting hypotension and va sodilation in the vascular system. Sugo et ai. (l994a, b) have reported that cultured vascular endothelial cells and smooth-muscle cells produce and secrete adrenomedullin and that its mRNA is constitutively expressed in both. This peptide may represent a new member of the group of endothelium-derived relaxing factors, owing to its ac tions at receptors positively coupled to cAMP formation in both endothelial and smooth-muscle cells.
Previous reports have stated that adrenomedullin as well as CGRP exert vasodilator activity in the cerebral circulation in vitro, in situ, and in vivo (Suzuki et aI., 1989; Suzuki, 1993; Baskaya et aI., 1995; Wang et aI., 1995) . This vasodilator activity of adrenomedullin was inhibited by CGRPS_ 3 7, an antagonist of CGRP, but was unaffected by � -nitro-L-arginine methylester (L-NAME) or indomethacin administration in dogs (Baskaya et aI., 1995; Wang et aI., 1995) . However, the direct evidence of the effect of adrenomedullin on the regional cerebral blood flow (rCBF) has not been avail able. The present investigation was therefore undertaken to study the effect of adrenomedullin on rCBF measured via a laser Doppler flowmeter device in rats. We also investigated the effect of the intravenous infusion of ad reno medullin on the volume of ischemic brain injury in a model of middle cerebral artery (MCA) occlusion in spontaneously hypertensive rats (SHRs).
METHODS

Preparation of animals
All protocols and surgical procedures were approved by the Institute for Laboratory Animal Research, Nagoya Univer sity School of Medicine. For this study, we used adult, male Sprague-Dawley (SO) rats, weighing 300-400 g and SHRs, weighing 2S0-300 g. Anesthesia consisted of 2% halothane for induction and 1.2% halothane plus SO% nitrous oxide-SO% oxygen�'or maintenance. Animals were ventilated mechanically with a rodent ventilator (SN-480-7; Shinano, Tokyo, Japan) through an endotracheal tube (polyethylene tubing, PE-240).
The respiratory volume and rate were adjusted to maintain the P a02 between 100 and 200 mm Hg and the P ac02 between 30 and 40 mm Hg. The left femoral artery was cannulated for continuous arterial blood pressure monitoring and to obtain measurements of the arterial pH, P ac02 ' P a02' hemoglobin, and blood glucose concentration. These parameters were measured at least twice during the experimental procedure. The left femo ral vein was used for drug infusion. A rectal thermometer (BWT-lOO; Bio Research Center, Nagoya, Japan) was inserted, and the body temperature was maintained at 36.9 ± O.soC with a heating pad.
Regional CBF measurement
Changes of rCBF were recorded at the surface of the left parietal cortex using laser Doppler flowmeter probes attached to a laser flowmeter device (ALF 21R; Advance Co., Tokyo, Japan). After rats were placed in a stereotaxic frame, craniec tomy (O.S mm in diameter, 4-6 mm lateral and 1-2 mm caudal to the bregma) was performed with extreme care over the MCA territory, using a surgical blade to gently shave the bone. The dura was left intact. The probe of the laser Doppler flowmeter was advanced steadily, perpendicular to the cortical surface, using a micromanipulator (Z-I; Narishige, Tokyo, Japan). Care was taken to avoid placing the probe above the pial arteries and veins; although it touched, it did not indent the dura mater. To facilitate optimal laser Doppler flowmeter recording, the dura was kept moist with warmed saline. Changes in rCBF were expressed as the percentage from baseline rCBF assessed be fore drug administration.
Focal ischemia study
The left MCA and ipsilateral common carotid artery (CCA) of SHRs were occluded according to a modification of the Brint J Cereb Blood Flow Metab. Vol. 17, No.1. 1997 method, as previously described (Brint et a!., 1988; Koketsu et aI., 1992) . Briefly, after the left cervical common carotid artery had been exposed and a 3-0 silk suture had been positioned under it for the purpose of ligation following MCA occlusion, a I-cm skin incision was made at the midpoint between the left lateral canthus and anterior pinna in animals in the lateral po sition. A 3-mm craniectomy was performed at the junction of the zygoma and squamosal bone, and a 10-0 nylon suture was passed beneath the left MCA (just above the rhinal fissure) in preparation for ligation. Animals were then placed in a stereo taxic frame (SR-S; Narishige). A 3-mm burr hole was drilled with care over the cortical barrel fields (AP: 0-3.0 mm, ML: 4.0-7.0 mm). The rCBF was recorded on the surface of ex posed dura. After stabilization, adrenomedullin or vehicle was infused intravenously for 60 min; then the left MCA was li gated, followed by ipsilateral CCA occlusion. The rCBF was monitored continuously for �2 h before ischemia and 2 h fol lowing ischemia. 
Experimental protocol
Measurement of the volume of ischemic brain injury
Animals were killed 24 h after the ischemia experiments.
Their brains were quickly removed, placed in cold saline so lution for 10 min, and then cut into 7 x 2-mm coronal slices in a rodent brain matrix (RBM 4000C; Activational Systems, Warren, MI, U.S.A.). Sections were stained with 2% TTC (2,3,S-triphenyltetrazolium chloride monohydrate) as previ ously described (Bederson et aI., 1986; Koketsu et aI., 1992) .
The volume of ischemic brain injury was measured using a 
Materials
Rat adrenomedullin, human adrenomedullin, and human ad renomedullin22_52 were obtained from Peptide Institute (Osaka, Japan). TTC was obtained from Katayama Chemicals Co.
(Nagoya, Japan). All other chemicals were reagent grade.
Statistical analysis
Data are expressed as the mean ± SO and were analyzed by a repeated-measures analysis of variance (ANOV A) followed by contrasts in repeated measures design and Student ' s t test (Super ANOVA; Abacus, CA, U.S.A.). A P value of <0.05 was considered statistically significant.
RESULTS rCBF responses to rat adrenomedullin and human adrenomedullin
The intravenous infusion of 1.0 ml of saline for 60 min produced no significant change in rCBF (102 ± 7.6% of baseline, n = 5). The administration of 0.05 J.,Lg/kg/min of rat adrenomedullin for 60 min also did not result in a statistically significant change in rCBF compared with values obtained following saline infusion. However, the administration of 0. 1, 0.5, and 1.0 J.,Lg/kg/min of rat ad renomedullin increased the rCBF in a dose-dependent manner (Fig. 1 ). There were no significant changes in pH, P aco2' P a02' hemoglobin, or blood glucose concen trations before and after the infusion of adrenomedullin (Table 1 ). The initial mean arterial blood pressure ranged from 96 to 109 mm Hg in all groups of SD rats, and there were no statistical differences between groups with and without adrenomedullin ( Table 2) . We used a dose of 2.0 J.,Lg/kg/min of rat adrenomedullin in three rats, two of which suffered mild hypotension. We therefore decided to use 1.0 J.,Lg/kg/min as the maximal dose. The physi ologic data obtained at the end of the infusion of each dose are sumill arized in Table 1 . rCBF was plotted after 15, 30, 45, and 60 min of infusion. The statistically significant increase in rCBF was measured in groups receiving 0.5 or 1.0 J.,Lg/kg/min of rat adrenomedullin (Fig. 1) .
To investigate if rat adrenomedullin causes tachyphy laxis, we readministered 1.0 J.,Lg/kg/min of rat adreno medullin 2 h after the end of the first infusion. This second infusion of rat adrenomedullin demonstrated a significantly decreased effect on rCBF compared with that of the first infusion (n = 5, p < 0.0 1). The intrave nous infusion of human adrenomedullin at a dose of 1.0 J.,Lg/kg/min for 60 min produced less of an increase in rCBF compared with the same dose of rat adrenomedul lin (Fig. 2) . A significant difference existed between these two groups 60 min and beyond the start of the infusions. In the group of rats receiving human adreno medullin, rCBF returned to values similar to baseline within 30 min of the end of the infusion. In the group receiving rat adrenomedulIin, however, rCBF remained above baseline for an extended period (125 ± 6.2% of baseline at 90 min).
Effect of human adrenomedullin 22--52 on rCBF responses to rat adrenomedullin
Administration of the C-terminal fragment of human adrenomedullin, human adrenomedullin22_52, did not cause a significant change in rCBF from baseline. How ever, the simultaneous administration of human adreno medullin22_52 (0.5 and 5.0 J.,Lg/kg/min) and rat adreno medullin (0.5 J.,Lg/kg/min) suppressed the increase in rCBF in response to rat adrenomedullin in a dose dependent manner (Fig. 3) .
Effect of adrenomedullin on rCBF in the MCA occlusion model
In the MCA occlusion model in SHRs, preinfusion of 1.0 J.,Lg/kg/min of rat adrenomedullin increased rCBF in the ischemic hemisphere to 118 ± 6. 1 % of baseline. After MCA occlusion, rCBF fell to 23 ± 11.3% of baseline in the ischemic hemisphere of the control rats. In the pre treated group, occlusion reduced rCBF to 35 ± l7.3% of baseline in the ischemic hemisphere. At the end of infu sion (after 60 min of ischemia), rCBF values were 29 ± 15. 1 % and 45 ± 14.4% in the control and adrenomedullin groups, respectively (Fig. 4) , which did not reflect a sig nificant difference. Infusion of adrenomedullin in the MCA occlusion model did not affect the mean arterial blood pressure (Table 3) .
Effect of adrenomedullin on ischemic brain injury volume
In SHRs, the MCA occlusion model induced a highly reproducible ischemic brain injury that affected both the cortex and striatum. The total volume of ischemic brain injury, assessed from TTC-stained brain slices, was 288 ± 35 mm 3 in the control SHR group (n = 7). Treatment a Values obtained at the end of infusion. Values are expressed as the mean ± SD. There was no significant difference among any of the groups in any physiological parameter. A, saline in SD rats; B, 0.05 fLg/kg/ml of rat adrenomedullin in SD rats; C, 0.1 fLg/kg/ml of rat adrenomedullin in SD rats; D, 0.5 fLg/kg/ml of rat adrenomedullin in SD rats; E, 1.0 fLg/kg/ml of rat adrenomedullin in SD rats; F, 1.0 fLg/kg/ml of human adrenomedullin in SD rats; G, 0.5 fLg/kg/ml of human adrenomedullin22_52 in SD rats; H, 5.0 fLg/kg/ml of human adrenomedullin22_52 in SD rats; I, saline in SHR; J, 1.0 fLg/kg/ml of rat adrenomedullin in SHR. with 1.0 j.Lg/kg/min of adrenomedullin for 60 min before occlusion and for 60 min following occlusion reduced the ischemic brain injury volume to 232 ± 35 mm 3 (n = 7). A statistically significant difference existed between the two groups (p < 0.05). Thus, the total volume of ischemic brain injury was reduced by 19.5% with adre nomedullin treatment (Fig. 5 ).
DISCUSSION
This study has shown that the intravenous administra tion of rat adrenomedullin produces a dose-dependent increase in rCBF in anesthetized SD rats without affect ing systemic blood pressure or blood gas values. The maximum increase in rCBF induced by adrenomedullin was -45%. In a previous study, we have shown that this peptide elicits an increase in vertebral artery blood flow and vasodilation in the major cerebral arteries on angi ography in dogs in vivo (Baskaya et aI., 1995) . Vasodi lator responses to adrenomedullin in isolated dog pial arteries (Baskaya et aI., 1995; Wang et aI., 1995) , rat pial arteries in situ (Wang et aI., 1995) , and rat intracerebral arterioles (unpublished data) also have indicated the po tent vasoactive effect of adrenomedullin on cerebral blood vessels. The evidence obtained in the present study supports the idea that adrenomedullin plays an important role as a vasoactive peptide in the control of CBF.
The increase in rCBF induced by adrenomedullin was inhibited in a dose-dependent manner by the simulta neous administration of the C-terrninal fragment of ad renomedullin, adrenomedullin22_52, which lacks the common cyclic structure. It also has been demonstrated that the increase in vertebral artery blood flow caused by adrenomedullin and the vasodilator effect of adreno medullin on the isolated basilar artery in dogs can be inhibited by an antagonist of the calcitonin gene-related peptide receptor, CORPs_37 (Baskaya et aI., 1995; Wang et aI., 1995) . These results suggest that adrenomedullin Effect of rat adrenomedullin on regional cerebral blood flow (rCBF) in the middle cerebral artery (MCA) occlusion model in spontaneously hypertensive rats. Changes in rCBF are ex pressed as a percentage of the baseline rCBF. Infusion of 1 ml/h of saline (control group) or 1 IJg/kg/min of rat adrenomedullin (pretreated group) was started 1 h before and continued through out 1 h of left MCA occlusion. In rats that received saline, rCBF remained essentially stable throughout the pre-ischemic infusion period (104 ± 5.5% of baseline); the intravenous infusion of AM produced a valuable increase in rCBF throughout the same pe riod (118 ± 6.1 % of baseline). During the ischemic period, in rats that received adrenomedullin (AM), the rCBF appeared to be maintained at a higher level than that in the saline (control) group, although a significant difference did not exist. Values are means ± SO. The number of animals is indicated in parentheses. *p < 0.05 versus control group. interacts with the common receptors of CORP, a ho mologous peptide, in vascular smooth-muscle cells. A study with iodine 125-labeled rat adrenomedullin has established the presence of a single class of high-affinity binding sites for adrenomedullin in cultured vascular smooth-muscle cells from rat thoracic aorta (Eguchi et aI., 1994) . Furthermore, CORP was shown to interact with these adrenomedullin receptors.
In contrast with the receptors in vascular smooth muscle cells, those in endothelial cells seem to be more specific for adrenomedullin, since iodine 125-labeled adrenomedullin binding was not displaced by CORP in bovine aortic endothelial cells (Shimekake et aI., 1995) . The vasodilator effects of adrenomedullin, therefore, may be dependent on at least two mechanisms. The first involves a direct action of adrenomedullin on vascular smooth-muscle cells mediated via receptors in which binding is coupled to the accumulation of intracellular cyclic AMP (Ishizaki et aI., 1994) . The second mecha nism involves an indirect action of adrenomedullin on endothelial cells mediated through receptors in which binding is coupled to the release of nitric oxide, by in creasing intracellular Ca 2 + concentrations or activating phospholipase C, in addition to the accumulation of in tracellular cyclic AMP (Shimekake et aI., 1995) . The stimulating activity of adrenomedullin on the re- aimed at reducing stroke size, the present findings indi cate that the protection afforded by adrenomedullin is indeed substantial. We suggest that hemodynamic mechanisms, including increased collateral tlow, may explain the reduced volume of ischemic brain injury after MeA occlusion following the intravenous infusion of adrenomedullin. It has been proposed that even small increases in reBF may improve tissue outcome during focal ischemia, especially that involving the periischemic zone and ischemic penumbra. In addition, adrenomedul lin may have differing protective effects against ischemic insults. A recent report showed that adrenomedullin mRNA expression is significantly increased in the isch emic cortex in the rat focal stroke model of MeA occlu sion (Wang et aI., 1995) . The details regarding the spe cific involved mechanisms of adrenomedullin expressed in the ischemic brain will require further study.
In conclusion, adrenomedullin is a vasoactive peptide of a new category constitutively secreted from both vas cular endothelial and smooth-muscle cells in addition to other tissues. Adrenomedullin of concentrations not af fecting the systemic blood pressure may participate in the regulation of reBF by adjusting the cerebral vascular tonus. This peptide suppresses the reduction in reBF following an ischemic insult, hence preventing ischemic brain injury. The clinical relevance of adrenomedullin remains to be evaluated, especially in postocclusion treatment.
